NV-RIMINI-STREET
Rimini Street, Inc . (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced the first offerings in a family of solutions designed to provide improved competitive advantage to organizations with mature and valuable enterprise software investments that can be used as a foundation for innovation. Rimini Street’s new solutions can enable an organization to quickly and cost-effectively modernize their current enterprise software with the latest desired features and capabilities, future-proof their technical platforms against yet-unknown technology changes, and secure their systems against a constantly evolving threat environment. Rimini Street’s new solutions enable organizations to leverage their existing systems as a solid foundation for an innovative hybrid IT strategy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180424006173/en/
“Innovation by Extension” Maximizes ROI and Accelerates Competitive Advantage
Organizations have invested significant money, labor and time in their current mission-critical enterprise software systems and want to maximize the ROI and extend the life of these investments while focusing new investments on innovations that can rapidly drive growth and competitive advantage. Rimini Street’s extensibility solutions are designed to help companies achieve these objectives by delivering cost effective, easy to deploy functional and technical capabilities to current, mature enterprise software systems, allowing CIOs to access and leverage innovation quickly without having to undertake costly, disruptive upgrades, cost-prohibitive replacements or wait potentially years for the vendor to deliver functionality that is needed now.
Rimini Street’s new family of extensibility solutions can also lay the foundation for an organizations’ hybrid IT strategy that combines existing, mature on-premise systems of record with systems of engagement that may include innovative cloud-based technologies. Innovation can be funded by savings that result from switching to Rimini Street’s award-winning support program.
Rimini Street’s first in a new family of extensibility solutions include the following:
- Rimini Street Mobility – Allows users to quickly create and distribute a mobile application in days, delivering the fastest time to value and no business disruption. All existing processes, customizations and logic are fully usable, so no software release migrations or upgrades are required.
- Rimini Street Analytics – Enables users to make better, faster decisions across the enterprise with a cost-effective, quick-to-deploy and easy to implement self-service business intelligence platform. Users can connect and analyze data from multiple sources to create their own custom reports and dashboards on the fly.
- Rimini Street Advanced Database Security – A next-generation security solution that identifies and intercepts attempted exploits of database vulnerabilities before they reach their target, without requiring any changes to the database code. Rimini Street Advanced Database Security was launched in 2017.
“Customers in today’s IT landscape want to achieve more value out of their current enterprise software platform and seek options that help them modernize their platforms without the hassles of expensive and endless upgrades. Leaders also seek agility and a competitive advantage in achieving corporate goals. This new standard of software support helps them to achieve these goals, and allows customers to fully maximize their enterprise software investments with the very best ROI,” said R ‘Ray’ Wang, Principal Analyst and CEO of Constellation Research.
Mobility Solution Provides Business Agility and Quick Wins
Most organizations have business demand for mobilizing functions across the enterprise to support their digital transformation efforts, but are held back by the cost, time and effort required to develop and launch new mobile applications. In addition, many mobile solutions involve customized code which is not supported by the software vendor.
Rimini Street Mobility addresses these challenges by providing a best-of-breed mobility framework that is designed to allow end-users to quickly and easily create their own mobile capabilities. Rimini Street Mobility can lower the cost of mobilizing enterprise applications, and can reduce the time to develop and deliver new applications from potentially months to just days, delivering quick wins to the organization.
Cost Effective, Actionable Data Intelligence
Organizations are increasingly turning to analytics software to support the needs of their departmental end-users to have actionable data intelligence at their fingertips in real time. Their users require ease of use, compatibility with all their devices and the ability to simplify the data for reporting purposes. However, current options available from the enterprise software vendors can be expensive to license and time-consuming to implement, and often limited to a single data source. Rimini Street Analytics provides organizations and their end-users the ability to cost-effectively procure and rapidly install and access a business intelligence solution that lets them pull data from multiple data sources including enterprise applications, databases or cloud solutions.
Rimini Street Advanced Database Security
Also part of the extensibility solutions portfolio is Rimini Street Advanced Database Security. Launched in 2017 and available for Oracle, SAP, IBM and Microsoft databases under support contracts with Rimini Street, the product is a next-generation database security solution that protects databases from known and unknown vulnerabilities, faster and less expensive than traditional vendor security patches, through the use of modern virtual patching. The solution blocks attempted attacks before they reach the database without the need for regression testing or impacting production systems.
Rimini Street plans to continue to advance the scope and breadth of its extensibility solutions over time. In addition, the Company offers a deep portfolio of technical services which enable clients to further future-proof existing systems by addressing interoperability issues and avoid unnecessary upgrades of hardware, operating systems, databases, middleware and browsers.
“Rimini Street has been our trusted enterprise software support provider for more than eight years, and during this time we have not only received high quality, ultra-responsive support for our core platform, but have also saved significant budget in our total maintenance costs each and every year. But Rimini Street isn’t content to just resolve break/fix issues,” said Eric Robinson, CIO of Color Spot. “They added a new dimension by offering solutions which can quickly extend our ERP with needed mobility and analytics capabilities all without a costly upgrade. We look forward to exploring these new capabilities as we continue to modernize our operations and gain competitive edge.”
“Clients are looking for simple, affordable and streamlined solutions that work securely across their enterprise application portfolio, without having to upgrade or replace their current enterprise software investment just to reap the benefits of new, modern application capabilities and technologies,” said Seth A. Ravin , Rimini Street CEO. “Our solutions ensure that an organizations’ existing applications are modernized, its technology is protected against future changes, and its systems protected with innovative security solutions. Existing enterprise software investments can serve for many years as the foundation for a hybrid IT strategy that delivers competitive advantage through ‘Innovation by Extension’ – all supported by Rimini Street’s award-winning support program.”
Pricing and Availability
Rimini Street offers attractive packaged pricing and annual subscription-pricing for all of the extensibility solutions. Rimini Street Mobility, Rimini Street Analytics and Rimini Street Advanced Database Security are immediately available.
About Rimini Street, Inc.
Rimini Street, Inc. (Nasdaq: RMNI) is a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products. The company has redefined enterprise software support services since 2005 with an innovative, award-winning program that enables licensees of IBM, Microsoft, Oracle, SAP and other enterprise software vendors to save up to 90 percent on total support costs. Clients can remain on their current software release without any required upgrades for a minimum of 15 years. Over 1,560 global Fortune 500, midmarket, public sector and other organizations from a broad range of industries currently rely on Rimini Street as their trusted, third-party support provider. To learn more, please visit https://www.riministreet.com , follow @riministreet on Twitter and find Rimini Street on Facebook and LinkedIn . (C-RMNI)
Forward-Looking Statements
Certain statements included in this communication are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “may,” “should,” “would,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “seem,” “seek,” “continue,” “future,” “will,” “expect,” “outlook” or other similar words, phrases or expressions. These forward-looking statements include, but are not limited to, statements regarding our first quarter and annual 2018 revenue guidance, industry, future events, future opportunities and growth initiatives, estimates of Rimini Street’s total addressable market, and projections of customer savings. These statements are based on various assumptions and on the current expectations of management and are not predictions of actual performance, nor are these statements of historical facts. These statements are subject to a number of risks and uncertainties regarding Rimini Street’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, changes in the business environment in which Rimini Street operates, including inflation and interest rates, and general financial, economic, regulatory and political conditions affecting the industry in which Rimini Street operates; adverse litigation developments or government inquiry; the final amount and timing of any refunds from Oracle related to our litigation; our ability to refinance existing debt on favorable terms; changes in taxes, laws and regulations; competitive product and pricing activity; difficulties of managing growth profitably; the loss of one or more members of Rimini Street’s management team; uncertainty as to the long-term value of RMNI common stock; and those discussed in Rimini Street’s Annual Report on Form 10-K filed on March 15, 2018 under the heading “Risk Factors,” as updated from time to time by Rimini Street’s Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings by Rimini Street with the Securities and Exchange Commission. There may be additional risks that Rimini Street presently knows or that Rimini Street currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements provide Rimini Street’s expectations, plans or forecasts of future events and views as of the date of this communication. Rimini Street anticipates that subsequent events and developments will cause Rimini Street’s assessments to change. However, while Rimini Street may elect to update these forward-looking statements at some point in the future, Rimini Street specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Rimini Street’s assessments as of any date subsequent to the date of this communication.
© 2018 Rimini Street, Inc. All rights reserved. “Rimini Street” is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180424006173/en/
Contact:
Rimini Street, Inc.
Michelle McGlocklin, +1 925-523-8414
mmcglocklin@riministreet.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
